Omalizumab in the treatment of asthma

References

• Asher MI, Montefort S, Bjorksten B et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet368(9537), 733–743 (2006).
   PubMed Web of Science ®Google Scholar
• Pleis JR, Lethbridge-Cejku M. Summary health statistics for U. S. adults: National Health Interview Survey 2005. Vital Health Stat.10(232), 1–153 (2006).
   Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J. Allergy Clin. Immunol.120(5 Suppl.), S94–S138 (2007).
   PubMed Web of Science ®Google Scholar
• Karpel J, Massanari M, Geba GP, Kianifard F, Inhaber N, Zeldin RK. Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. Ann. Allergy Asthma Immunol.105(6), 465–470 (2010).
   PubMed Web of Science ®Google Scholar
• Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc ε RI expression and function. J. Allergy Clin. Immunol.114(3), 527–530 (2004).
   PubMed Web of Science ®Google Scholar
• Lin H, Boesel KM, Griffith DT et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J. Allergy Clin. Immunol.113(2), 297–302 (2004).
   PubMed Web of Science ®Google Scholar
• Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int. Arch. Allergy Immunol.131(1), 46–52 (2003).
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson SJ, Kraft M et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med.170(6), 583–593 (2004).
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy64(12), 1728–1736 (2009).
   PubMed Web of Science ®Google Scholar
• Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics113(4), e308–e312 (2004).
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med.155(6), 1828–1834 (1997).
   PubMed Web of Science ®Google Scholar
• Hanf G, Noga O, O’Connor A, Kunkel G. Omalizumab inhibits allergen challenge-induced nasal response. Eur. Respir. J.23(3), 414–418 (2004).
   PubMed Web of Science ®Google Scholar
• Ong YE, Menzies-Gow A, Barkans J et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J. Allergy Clin. Immunol.116(3), 558–564 (2005).
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Brookman L, Fox H et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr. Med. Res. Opin.19(6), 491–498 (2003).
   PubMed Web of Science ®Google Scholar
• Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N. Engl. J. Med.355(12), 1281–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol.108(2), 184–190 (2001).
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics108(2), E36 (2001).
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J.18(2), 254–261 (2001).
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy34(4), 632–638 (2004).
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy59(7), 709–717 (2004).
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy60(3), 309–316 (2005).
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med.154(9), 573–582 (2011).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M et al. Italian real-life experience of omalizumab. Respir. Med.104(10), 1410–1416 (2010).
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R et al. ‘Real-life’ effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir. Med.103(11), 1633–1642 (2009).
   PubMed Web of Science ®Google Scholar
• Molimard M, Buhl R, Niven R et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir. Med.104(9), 1381–1385 (2010).
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J. Allergy Clin. Immunol.124(6), 1210–1216 (2009).
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med.364(11), 1005–1015 (2011).
   PubMed Web of Science ®Google Scholar
• Korn S, Schumann C, Kropf C et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann. Allergy Asthma Immunol.105(4), 313–319 (2010).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy66(5), 671–678 (2011).
   PubMed Web of Science ®Google Scholar
• Corren J, Shapiro G, Reimann J et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J. Allergy Clin. Immunol.121(2), 506–511 (2008).
   PubMed Web of Science ®Google Scholar
• Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J. Asthma48(4), 387–392 (2011).
   PubMed Web of Science ®Google Scholar
• Nopp A, Johansson SG, Adedoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy65(1), 56–60 (2010).
   PubMed Web of Science ®Google Scholar
• Long AA, Fish JE, Rahmaoui A et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann. Allergy Asthma Immunol.103(3), 212–219 (2009).
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin. Exp. Allergy39(6), 788–797 (2009).
   PubMed Web of Science ®Google Scholar
• Cox L, Lieberman P, Wallace D et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J. Allergy Clin. Immunol.128(1), 210–212 (2011).
   PubMed Web of Science ®Google Scholar
• Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. Int. J. Epidemiol.22(6), 976–982 (1993).
   PubMed Web of Science ®Google Scholar
• Reynolds P, Kaplan GA. Asthma and cancer. Am. J. Epidemiol.125(3), 539–540 (1987).
   PubMed Web of Science ®Google Scholar
• Kallen B, Gunnarskog J, Conradson TB. Cancer risk in asthmatic subjects selected from hospital discharge registry. Eur. Respir. J.6(5), 694–697 (1993).
   PubMed Web of Science ®Google Scholar
• Cruz AA, Lima F, Sarinho E et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin. Exp. Allergy37(2), 197–207 (2007).
   PubMed Web of Science ®Google Scholar
• Ruppert AM, Averous G, Stanciu D et al. Development of Churg–Strauss syndrome with controlled asthma during omalizumab treatment. J. Allergy Clin. Immunol.121(1), 253–254 (2008).
   PubMed Web of Science ®Google Scholar
• Bargagli E, Madioni C, Olivieri C, Penza F, Rottoli P. Churg–Strauss vasculitis in a patient treated with omalizumab. J. Asthma45(2), 115–116 (2008).
   PubMed Web of Science ®Google Scholar
• Omalizumab: cardiac adverse effects. Prescrire Int.19(106), 75 (2009).
   Google Scholar